drugset / Trial / NCT00732966

Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

NCT00732966

Unknown 30 enrolled Assaf-Harofeh Medical Center
NaSingle-groupOpen-label

Summary

Most Angiotensin receptor blocker's (ARBs) are metabolized by cytochrome P4502C9 (CYP2C9), one of the major isoforms of the cytochrome P450 in human liver microsome. The purpose of this study is to evaluate whether CYP2C9 polymorphism has a significant clinical influence on the blood pressure lowering effect of losartan and valsartan. Weather there is a genetic importance in choosing the right ARB for the right patient.

Timeline

Start
2008-09
Primary completion
2009-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 50 mg Oral
Subject Valsartan Small molecule 160 mg

Indications